SLC5A2 and cervical carcinoma: After the follow-up period, 172 and 443 cervical cancer events were reported in the SGLT2 inhibitor group and control group, respectively, after 2:1 sex and age matching (aHR, 0.77; 95% CI, 0.63-0.93, P = 0.0081; Table 2).